Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Rhea-AI Summary
Ceribell (Nasdaq: CBLL) announced that CEO and co‑founder Jane Chao, Ph.D., and CFO Scott Blumberg will take part in a fireside chat at the Bank of America Securities 2026 Health Care Conference.
The event is scheduled for Wednesday, May 13, 2026 at 3:40 p.m. PST / 6:40 p.m. EST. According to Ceribell, a live and archived webcast will be available in the company's Investor Relations section at https://investors.ceribell.com/.
Positive
- None.
Negative
- None.
News Market Reaction – CBLL
In the Apr 30 session, CBLL gained 4.73%, reflecting a moderate positive market reaction. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Earnings date notice | Neutral | -0.9% | Scheduled Q1 2026 earnings release and conference call announcement. |
| Feb 24 | Earnings results | Positive | -4.8% | Reported strong Q4 and FY 2025 growth, margins, guidance and cash balance. |
| Feb 18 | Investor conferences | Neutral | +1.8% | Participation in March 2026 Raymond James and TD Cowen investor events. |
| Feb 10 | Earnings date notice | Neutral | -1.1% | Set date and webcast details for Q4 and FY 2025 results release. |
| Jan 05 | Regulatory milestone | Positive | -2.3% | FDA Breakthrough Device Designation for LVO stroke detection solution. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Operational and regulatory positives, including strong growth and FDA milestones, have often been followed by negative or muted next-day price reactions.
This announcement continues Ceribell’s pattern of investor outreach, following multiple conference participations and earnings communications. Recent history includes Q4 and full-year 2025 results with $24.8M Q4 revenue and $89.1M for 2025 plus several FDA clearances. Earlier in 2026, the company reported a Breakthrough Device Designation for LVO stroke detection. Despite these milestones, next-day moves around earnings and regulatory news were negative, while prior conference participation on Feb 18, 2026 saw a modest positive reaction, suggesting conferences have drawn more balanced responses than major data or earnings releases.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Bank of America Securities 2026 Health Care Conference. The fireside chat will take place on Wednesday, May 13, 2026, at 3:40 p.m. Pacific Standard Time / 6:40 p.m. Eastern Standard Time.
Event: Bank of America Securities 2026 Health Care Conference
Date: Wednesday, May 13, 2026
Time: 3:40 p.m. PST / 6:40 p.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston
Gilmartin Group
Investors@ceribell.com
Media Contact
Brian Price
Press@ceribell.com
